These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2524303)

  • 1. Clinical significance of differences in bioavailability of medroxyprogesterone acetate preparations.
    Stockdale AD; Rostom AY
    Clin Pharmacokinet; 1989 Mar; 16(3):129-33. PubMed ID: 2524303
    [No Abstract]   [Full Text] [Related]  

  • 2. The pharmacokinetics of medroxyprogesterone acetate following two different loading dose schedules in advanced carcinoma of the breast.
    Canney PA; Dowsett M; Priestman TJ
    Br J Cancer; 1988 Jul; 58(1):73-6. PubMed ID: 2971386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Hormone therapy in metastasized breast cancer. Criteria for establishing indications and implementing high-dose medroxyprogesterone acetate therapy].
    Possinger K; Wagner H; Langecker P; Schmid L; Willich S; Wilmanns W
    Fortschr Med; 1987 Jul; 105(22):421-4. PubMed ID: 2958397
    [No Abstract]   [Full Text] [Related]  

  • 4. Medroxyprogesterone acetate: variation in serum concentrations achieved with three commercially available preparations.
    Stockdale AD; Chapman D; Mould GP; Rostom AY
    Cancer Treat Rep; 1987 Sep; 71(9):813-5. PubMed ID: 2957052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Hormonal control of disseminated breast cancer].
    Voznyĭ EK; Meshcheriakova NG; Biakhov MIu; Vasiuta NIu
    Sov Med; 1990; (6):94-7. PubMed ID: 2144368
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients.
    Etienne MC; Milano G; Frenay M; Renee N; Francois E; Thyss A; Schneider M; Namer M
    J Clin Oncol; 1992 Jul; 10(7):1176-82. PubMed ID: 1535103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Megestrol acetate versus medroxyprogesterone acetate in the treatment of metastasizing breast cancers. Intermediate report of a multicenter phase III study].
    Wander HE; Kleeberg UR; Gärtner E; Hartlapp J; Scherpe A; Bönisch E; Nagel GA
    Onkologie; 1987 Apr; 10(2):104-6. PubMed ID: 2954006
    [No Abstract]   [Full Text] [Related]  

  • 8. [Aminoglutethimide plus high-dose medroxyprogesterone acetate versus aminoglutethimide plus cortisone in therapy of metastasizing breast cancer. An AIO phase III study].
    Wander HE; Kleeberg UR; Essers U; Blossey HC; Nagel GA
    Onkologie; 1987 Oct; 10(5):321-3. PubMed ID: 2960938
    [No Abstract]   [Full Text] [Related]  

  • 9. Therapeutic activity of medroxyprogesterone acetate in metastatic breast cancer: a correlation between estrogen receptors and various dosages.
    De Lena M; Villa S; Di Fronzo G
    Recent Results Cancer Res; 1984; 91():243-7. PubMed ID: 6203147
    [No Abstract]   [Full Text] [Related]  

  • 10. Improved bioavailability of a new oral preparation of medroxyprogesterone acetate.
    Etienne MC; Milano G; René N; Benedetti MS; Efthymiopoulos C; Vo Van ML; Hurteloup P; Montcuquet P; Frenay M; Namer M
    J Pharm Sci; 1991 Dec; 80(12):1130-2. PubMed ID: 1839998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of carcinoma of the breast with high dose oral medroxyprogesterone acetate: does increased bioavailability improve the therapeutic ratio?
    Roberts JT; Bates T; Bozzino JM; Brock JE; Clarke DG; Durrant KR; Evans RG; Tobias JS
    Clin Oncol (R Coll Radiol); 1990 Nov; 2(6):324-7. PubMed ID: 2149061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medroxyprogesterone acetate: steady-state pharmacokinetics bioequivalence of two oral formulations.
    Pollow K; Kreienberg R; Di Pietro N
    J Cancer Res Clin Oncol; 1989; 115(4):397-9. PubMed ID: 2527239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Depot medroxyprogesterone and breast cancer.
    Day BJ; McCallum AB; Zambrano D; Tong DD
    N Z Med J; 1990 Jul; 103(893):327-8. PubMed ID: 2142520
    [No Abstract]   [Full Text] [Related]  

  • 14. Oral route administration of medroxyprogesterone acetate (MAP) at high doses in the treatment of advanced breast cancer: clinical results.
    Guarnieri A; Tucci E; D'Aniello C; Carli A; Mariani L; De Stefano A; Nardi P
    Chemioterapia; 1984 Oct; 3(5):320-3. PubMed ID: 6241848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Gestagen therapy of breast cancer. Effect of high doses on the blood coagulation system].
    Schenk H; Fereberger W
    MMW Munch Med Wochenschr; 1983 Oct; 125(40):875-6. PubMed ID: 6226871
    [No Abstract]   [Full Text] [Related]  

  • 16. [Medroxyprogesterone acetate as glucocorticoid in combination with aminoglutethimide in the treatment of metastatic breast cancer].
    Blossey HC; Wander HE; Nagel GA; Köbberling J; Kleeberg U
    Onkologie; 1982 Aug; 5 Suppl():34-41. PubMed ID: 6290955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Adjuvant hormone therapy of primary breast cancer. Review of the literature].
    Focan C
    Rev Med Liege; 1991 May; 46(5):270-8. PubMed ID: 1830160
    [No Abstract]   [Full Text] [Related]  

  • 18. [Phase II study of medroxyprogesterone acetate in advanced breast cancer].
    Ueno K; Ogawa M; Horikoshi N; Inoue K; Mukaiyama T; Nakamura T; Ito Y; Imajo K; Ozeki H
    Gan To Kagaku Ryoho; 1986 Oct; 13(11):3198-202. PubMed ID: 2946264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The elevation of serum iron level with oral administration of medroxyprogesterone acetate (MPA) in patients with breast cancer].
    Kadota K; Wada T; Watatani M; Houjou T; Mori N; Yasutomi M
    Gan To Kagaku Ryoho; 1991 May; 18(6):983-7. PubMed ID: 1827574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of hormone therapy in metastasizing breast cancer].
    Samonigg H
    Wien Med Wochenschr; 1985 Dec; 135(23-24):602-7. PubMed ID: 2937208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.